Rheumnow Podcast

Dr. Cush
  • 0.0 (0)
  • Medicina
  • Cada semana

Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com

  1. hace 1 día

    ICYMI: Great Lectures; Great Presentations

    Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

    28 min

  2. 26 jun

    Generic Tofacitinib (6.26.2026)

    Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

    30 min
  3. DERM on RheumNow (June 2026)

    26 jun

    DERM on RheumNow (June 2026)

    The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr   - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB,  p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8.  Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25).   - Probiotics in Psoriatic Arthritis. (POS0290)    66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks.  This trial proves no significant effect with oral probiotic supplementation in PsA.  - CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ - Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B

    18 min

  4. 19 jun

    Do You Zoster Vaccinate? (6.19.2026)

    Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

    29 min
  5. RheumNow EULAR 2026 Rheumatology Round Up

    12 jun

    RheumNow EULAR 2026 Rheumatology Round Up

    Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

    56 min
  6. EULAR 2026 RA Topic Panel

    11 jun

    EULAR 2026 RA Topic Panel

    Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping RA practice right now.

    54 min
  7. CAR-T Topic Panel EULAR 2026

    10 jun

    CAR-T Topic Panel EULAR 2026

    Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

    38 min
  8. EULAR 2026 PsA Update What's Changing in Psoriatic Arthritis Care?

    9 jun

    EULAR 2026 PsA Update What's Changing in Psoriatic Arthritis Care?

    Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

    49 min
Ver todo (998)

Acerca de

Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com

Información

  • Creador
    Dr. Cush
  • Años de actividad
    2016 - 2026
  • Episodios
    998
  • Clasificación
    Apto
  • Copyright
    © All rights reserved
  • Mostrar sitio web
    Rheumnow Podcast

También te podría interesar